Overexpression of LIMP-2 in murine neuroblastoma as well as human glioma cells accelerated the clearance of α-synuclein, demonstrating the potential of exogenous expression of LIMP-2 in GD gene therapy (Table 1) [57]. Here, SCARB2 is linked to central nervous system cancer.